StockNews.com Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) to Sell

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Separately, Mizuho reduced their target price on Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday.

Adaptimmune Therapeutics Stock Performance

Shares of Adaptimmune Therapeutics stock opened at $1.11 on Friday. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05. The company has a fifty day moving average of $1.27 and a 200-day moving average of $0.99. The stock has a market capitalization of $273.97 million, a price-to-earnings ratio of -1.50 and a beta of 2.44.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative return on equity of 213.43%. On average, equities research analysts forecast that Adaptimmune Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Key Client Fiduciary Advisors LLC lifted its position in Adaptimmune Therapeutics by 6.4% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares during the period. Harbor Capital Advisors Inc. raised its stake in Adaptimmune Therapeutics by 9.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 13,317 shares during the last quarter. Boulder Hill Capital Management LP purchased a new stake in Adaptimmune Therapeutics during the 1st quarter valued at $143,000. JTC Employer Solutions Trustee Ltd purchased a new position in shares of Adaptimmune Therapeutics in the 1st quarter worth $41,000. Finally, Columbia Advisory Partners LLC bought a new stake in shares of Adaptimmune Therapeutics in the first quarter worth $25,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.